Shares of gene therapy company Taysha Gene Therapies (NASDAQ:TSHA) are soaring in the premarket session today after a key deal with Japan’s Astellas Pharma.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latter is making a strategic $50 million investment in Taysha in lieu of a 15% stake.
Astellas will also receive an exclusive option to gain the exclusive license for TSHA-102 for the treatment of Rett Syndrome and TSHA-120 for the treatment of giant axonal neuropathy (GAN).
Moreover, Astellas will also have one observer seat on Taysha’s Board.
Read full Disclosure
